AMOXAPINE |
ASENDIS |
CL-67772 |
DEFANYL |
ASENDIN |
AMOXAPIN |
2-CHLORO-11-(1-PIPERAZINYL)DIBENZ(B,F)(1,4)OXAZEPINE |
AMOXAPINA |
AMOXIPINE |
ASENDIN® |
AMOXEPINE |
DESMETHYLLOXAPIN |
AMOXAPINUM |
drugbank:00543 |
chemidplus:14028-44-5 |
rxcui:722 |
chembl:CHEMBL1113 |
pubchem.compound:2170 |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | antidepressant |
Drug Class | antidepressive agents, tricyclic |
Year of Approval | 1980 |
Drug Categories | adrenergic alpha-1 receptor antagonists |
Drug Categories | adrenergic alpha-antagonists |
Drug Categories | adrenergic antagonists |
Drug Categories | agents producing tachycardia |
Drug Categories | agents that produce hypertension |
Drug Categories | agents that reduce seizure threshold |
Drug Categories | anticholinergic agents |
Drug Categories | antidepressive agents, tetracyclic |
Drug Categories | antidepressive agents, tricyclic |
Drug Categories | antipsychotic agents |
Drug Categories | combined inhibitors of serotonin/norepinephrine reuptake |
Drug Categories | cytochrome p-450 cyp2d6 inhibitors |
Drug Categories | cytochrome p-450 cyp2d6 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | dopamine d2 receptor antagonists |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | histamine antagonists |
Drug Categories | histamine h1 antagonists |
Drug Categories | muscarinic antagonists |
Drug Categories | neurotoxic agents |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | potential qtc-prolonging agents |
Drug Categories | qtc prolonging agents |
Drug Categories | serotonergic drugs shown to increase risk of serotonin syndrome |
Drug Categories | serotonin 5-ht1 receptor antagonists |
Drug Categories | serotonin 5-ht2 receptor antagonists |
Drug Categories | serotonin receptor antagonists |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | True |
inhibitor (inhibitory) |
Trial Name | CRx-150, amoxapine plus dipyridamole |
Novel drug target | Established target |
Trial Name | CRx-119 |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Dopamine receptor antagonist |
antagonist (inhibitory) |
Mechanism of Interaction | Dopamine receptor antagonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Mechanism of Interaction | Dopamine receptor antagonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Dopamine receptor antagonist |
antagonist (inhibitory) |
Mechanism of Interaction | Dopamine receptor antagonist |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Norepinephrine transporter inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Serotonin transporter inhibitor |
Direct Interaction | yes |
AMOXAPINE | DrugBank Drug Name |
14028-44-5 | CAS Number |
Adisen | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Categories | adrenergic agents |
AMOXAPINE | Primary Drug Name |
Year of Approval | 1980 |
Drug Class | antidepressive agents, tricyclic |
Drug Indications | antidepressant |
Drug Class | Small Molecule |
FDA Approval | approved |
AMOXAPINE | GuideToPharmacology Ligand Name |
D09IOI | TTD Drug ID |
CHEMBL1113 | ChEMBL Drug ID |